Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. more
Time Frame | TMDX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.65% | -0.33% | -1.49% |
1-Month Return | -20.27% | -4.57% | -0.37% |
3-Month Return | -59.84% | -9.96% | 3.89% |
6-Month Return | -55.41% | -5.67% | 9.34% |
1-Year Return | -22.36% | 2.53% | 25.19% |
3-Year Return | 203.54% | -1.43% | 24.7% |
5-Year Return | 228.7% | 34.73% | 85.39% |
10-Year Return | 180.19% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 23.60M | 25.64M | 30.26M | 93.46M | 241.62M | [{"date":"2019-12-31","value":9.77,"profit":true},{"date":"2020-12-31","value":10.61,"profit":true},{"date":"2021-12-31","value":12.52,"profit":true},{"date":"2022-12-31","value":38.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 9.74M | 9.00M | 9.10M | 28.19M | 87.53M | [{"date":"2019-12-31","value":11.13,"profit":true},{"date":"2020-12-31","value":10.29,"profit":true},{"date":"2021-12-31","value":10.4,"profit":true},{"date":"2022-12-31","value":32.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 13.86M | 16.64M | 21.16M | 65.27M | 154.09M | [{"date":"2019-12-31","value":9,"profit":true},{"date":"2020-12-31","value":10.8,"profit":true},{"date":"2021-12-31","value":13.73,"profit":true},{"date":"2022-12-31","value":42.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | [{"date":"2019-12-31","value":84,"profit":true},{"date":"2020-12-31","value":92.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.89,"profit":true},{"date":"2023-12-31","value":91.21,"profit":true}] |
Operating Expenses | 43.47M | 43.02M | 60.59M | 96.71M | 182.82M | [{"date":"2019-12-31","value":23.78,"profit":true},{"date":"2020-12-31","value":23.53,"profit":true},{"date":"2021-12-31","value":33.14,"profit":true},{"date":"2022-12-31","value":52.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (29.60M) | (26.38M) | (39.43M) | (31.44M) | (28.73M) | [{"date":"2019-12-31","value":-2960300000,"profit":false},{"date":"2020-12-31","value":-2638400000,"profit":false},{"date":"2021-12-31","value":-3942800000,"profit":false},{"date":"2022-12-31","value":-3143700000,"profit":false},{"date":"2023-12-31","value":-2872700000,"profit":false}] |
Total Non-Operating Income/Expense | (8.26M) | (6.32M) | (8.63M) | (8.45M) | (6.14M) | [{"date":"2019-12-31","value":-825700000,"profit":false},{"date":"2020-12-31","value":-631700000,"profit":false},{"date":"2021-12-31","value":-862500000,"profit":false},{"date":"2022-12-31","value":-845400000,"profit":false},{"date":"2023-12-31","value":-613700000,"profit":false}] |
Pre-Tax Income | (33.51M) | (28.72M) | (44.18M) | (36.16M) | (26.67M) | [{"date":"2019-12-31","value":-3350700000,"profit":false},{"date":"2020-12-31","value":-2871600000,"profit":false},{"date":"2021-12-31","value":-4417900000,"profit":false},{"date":"2022-12-31","value":-3616500000,"profit":false},{"date":"2023-12-31","value":-2667100000,"profit":false}] |
Income Taxes | 40.00K | 32.00K | 36.00K | 66.00K | (1.64M) | [{"date":"2019-12-31","value":60.61,"profit":true},{"date":"2020-12-31","value":48.48,"profit":true},{"date":"2021-12-31","value":54.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2489.39,"profit":false}] |
Income After Taxes | (33.55M) | (28.75M) | (44.22M) | (36.23M) | (25.03M) | [{"date":"2019-12-31","value":-3354700000,"profit":false},{"date":"2020-12-31","value":-2874800000,"profit":false},{"date":"2021-12-31","value":-4421500000,"profit":false},{"date":"2022-12-31","value":-3623100000,"profit":false},{"date":"2023-12-31","value":-2502800000,"profit":false}] |
Income From Continuous Operations | (33.55M) | (28.72M) | (44.22M) | (36.23M) | (35.78M) | [{"date":"2019-12-31","value":-3354700000,"profit":false},{"date":"2020-12-31","value":-2871600000,"profit":false},{"date":"2021-12-31","value":-4421500000,"profit":false},{"date":"2022-12-31","value":-3623100000,"profit":false},{"date":"2023-12-31","value":-3577900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (33.55M) | (28.75M) | (44.22M) | (36.23M) | (25.03M) | [{"date":"2019-12-31","value":-3354700000,"profit":false},{"date":"2020-12-31","value":-2874800000,"profit":false},{"date":"2021-12-31","value":-4421500000,"profit":false},{"date":"2022-12-31","value":-3623100000,"profit":false},{"date":"2023-12-31","value":-2502800000,"profit":false}] |
EPS (Diluted) | (6.38) | (1.20) | (1.61) | (1.25) | (0.77) | [{"date":"2019-12-31","value":-638,"profit":false},{"date":"2020-12-31","value":-120,"profit":false},{"date":"2021-12-31","value":-161,"profit":false},{"date":"2022-12-31","value":-125,"profit":false},{"date":"2023-12-31","value":-77,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TMDX | |
---|---|
Cash Ratio | 5.50 |
Current Ratio | 8.20 |
Quick Ratio | 7.33 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TMDX | |
---|---|
ROA (LTM) | 2.84% |
ROE (LTM) | 19.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TMDX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.73 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.27 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TMDX | |
---|---|
Trailing PE | 66.34 |
Forward PE | 52.08 |
P/S (TTM) | 5.16 |
P/B | 9.87 |
Price/FCF | NM |
EV/R | 5.63 |
EV/Ebitda | 34.89 |
TransMedics Group Inc (TMDX) share price today is $63.9
Yes, Indians can buy shares of TransMedics Group Inc (TMDX) on Vested. To buy TransMedics Group Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TMDX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of TransMedics Group Inc (TMDX) via the Vested app. You can start investing in TransMedics Group Inc (TMDX) with a minimum investment of $1.
You can invest in shares of TransMedics Group Inc (TMDX) via Vested in three simple steps:
The 52-week high price of TransMedics Group Inc (TMDX) is $177.37. The 52-week low price of TransMedics Group Inc (TMDX) is $59.72.
The price-to-earnings (P/E) ratio of TransMedics Group Inc (TMDX) is 66.3441
The price-to-book (P/B) ratio of TransMedics Group Inc (TMDX) is 9.87
The dividend yield of TransMedics Group Inc (TMDX) is 0.00%
The market capitalization of TransMedics Group Inc (TMDX) is $2.07B
The stock symbol (or ticker) of TransMedics Group Inc is TMDX